Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
Add more filters










Publication year range
1.
Biochemistry ; 40(35): 10645-54, 2001 Sep 04.
Article in English | MEDLINE | ID: mdl-11524009

ABSTRACT

The steady-state kinetics of a full-length and truncated form of the type 2 human methionine aminopeptidase (hMetAP2) were analyzed by continuous monitoring of the amide bond cleavage of various peptide substrates and methionyl analogues of 7-amido-4-methylcoumarin (AMC) and p-nitroaniline (pNA), utilizing new fluorescence-based and absorbance-based assay substrates and a novel coupled-enzyme assay method. The most efficient substrates for hMetAP2 appeared to be peptides of three or more amino acids for which the values of k(cat)/K(m) were approximately 5 x 10(5) M(-1) min(-1). It was found that while the nature of the P1' residue of peptide substrates dictates the substrate specificity in the active site of hMetAP2, the P2' residue appears to play a key role in the kinetics of peptidolysis. The catalytic efficiency of dipeptide substrates was found to be at least 250-fold lower than those of the tripeptides. This substantially diminished catalytic efficiency of hMetAP2 observed with the alternative substrates MetAMC and MetpNA is almost entirely due to the reduction in the turnover rate (k(cat)), suggesting that cleavage of the amide bond is at least partially rate-limiting. The 107 N-terminal residues of hMetAP2 were not required for either the peptidolytic activity of the enzyme or its stability. Steady-state kinetic comparison and thermodynamic analyses of an N-terminally truncated form and full-length enzyme yielded essentially identical kinetic behavior and physical properties. Addition of exogenous Co(II) cation was found to significantly activate the full-length hMetAP2, while Zn(II) cation, on the other hand, was unable to activate hMetAP2 under any concentration that was tested.


Subject(s)
Aminopeptidases/metabolism , Metalloendopeptidases/metabolism , Amino Acid Substitution , Aminopeptidases/antagonists & inhibitors , Aminopeptidases/chemistry , Aminopeptidases/genetics , Anilides , Cations, Divalent , Circular Dichroism , Humans , Isoenzymes/genetics , Isoenzymes/metabolism , Kinetics , Metalloendopeptidases/antagonists & inhibitors , Metalloendopeptidases/chemistry , Metalloendopeptidases/genetics , Metals/metabolism , Norleucine/analogs & derivatives , Norleucine/biosynthesis , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Spectrophotometry , Substrate Specificity
2.
Mol Cell Neurosci ; 16(5): 609-19, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11083922

ABSTRACT

Sequential proteolytic processing of the Amyloid Precursor Protein (APP) by beta- and gamma-secretases generates the 4-kDa amyloid (A beta) peptide, a key component of the amyloid plaques seen in Alzheimer's disease (AD). We and others have recently reported the identification and characterisation of an aspartic proteinase, Asp2 (BACE), as beta-secretase. Here we describe the characterization of a second highly related aspartic proteinase, Asp1 as a second beta-secretase candidate. Asp1 is expressed in brain as detected at the mRNA level and at the protein level. Transient expression of Asp1 in APP-expressing cells results in an increase in the level of beta-secretase-derived soluble APP and the corresponding carboxy-terminal fragment. Paradoxically there is a decrease in the level of soluble A beta secreted from the cells. Asp1 colocalizes with APP in the Golgi/endoplasmic reticulum compartments of cultured cells. Asp1, when expressed as an Fc fusion protein (Asp1-Fc), has the N-terminal sequence ALEP..., indicating that it has lost the prodomain. Asp1-Fc exhibits beta-secretase activity by cleaving both wild-type and Swedish variant (KM/NL) APP peptides at the beta-secretase site.


Subject(s)
Amyloid beta-Protein Precursor/metabolism , Aspartic Acid Endopeptidases/metabolism , Glycoproteins/genetics , Glycoproteins/metabolism , Membrane Proteins/genetics , Membrane Proteins/metabolism , Amyloid Precursor Protein Secretases , Amyloid beta-Protein Precursor/analysis , Amyloid beta-Protein Precursor/chemistry , Animals , Aspartic Acid Endopeptidases/chemistry , Binding Sites/physiology , COS Cells , Cloning, Molecular , Endopeptidases , Female , Glycoproteins/analysis , Humans , Male , Membrane Proteins/analysis , Molecular Sequence Data , Rabbits , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Homology, Amino Acid
3.
Mol Cell Neurosci ; 14(6): 419-27, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10656250

ABSTRACT

The Alzheimer's disease beta-amyloid peptide (Abeta) is produced by excision from the type 1 integral membrane glycoprotein amyloid precursor protein (APP) by the sequential actions of beta- and then gamma-secretases. Here we report that Asp 2, a novel transmembrane aspartic protease, has the key activities expected of beta-secretase. Transient expression of Asp 2 in cells expressing APP causes an increase in the secretion of the N-terminal fragment of APP and an increase in the cell-associated C-terminal beta-secretase APP fragment. Mutation of either of the putative catalytic aspartyl residues in Asp 2 abrogates the production of the fragments characteristic of cleavage at the beta-secretase site. The enzyme is present in normal and Alzheimer's disease (AD) brain and is also found in cell lines known to produce Abeta. Asp 2 localizes to the Golgi/endoplasmic reticulum in transfected cells and shows clear colocalization with APP in cells stably expressing the 751-amino-acid isoform of APP.


Subject(s)
Alzheimer Disease/enzymology , Amyloid beta-Protein Precursor/metabolism , Aspartic Acid Endopeptidases/metabolism , Hippocampus/enzymology , Amino Acid Sequence , Amino Acid Substitution , Amyloid Precursor Protein Secretases , Animals , Aspartic Acid Endopeptidases/chemistry , Aspartic Acid Endopeptidases/genetics , COS Cells , Cathepsin D/metabolism , Cell Line , Cell Membrane/enzymology , Endopeptidases , Female , Humans , Middle Aged , Molecular Sequence Data , Mutagenesis, Site-Directed , Papain/chemistry , Recombinant Proteins/metabolism , Sequence Alignment , Sequence Homology, Amino Acid , Transfection
4.
Biochemistry ; 38(48): 15893-902, 1999 Nov 30.
Article in English | MEDLINE | ID: mdl-10625455

ABSTRACT

The nature of the inhibition of thiol proteases by a new class of mechanism-based inhibitors, 1,5-diacylcarbohydrazides, is described. These potent, time-dependent, active-site spanning inhibitors include compounds that are selective for cathepsin K, a cysteine protease unique to osteoclasts. The 1,5-diacylcarbohydrazides are slow substrates for members of the papain superfamily with inhibition resulting from slow enzyme decarbamylation. Enzyme-catalyzed hydrolysis of 2,2'-N, N'-bis(benzyloxycarbonyl)-L- leucinylcarbohydrazide is accompanied by formation of a hydrazide-containing product and a carbamyl-enzyme intermediate that is sufficiently stable to be observed by mass spectrometry and NMR. Stopped-flow studies yield a saturation limited value of 43 s(-)(1) for the rate of cathepsin K acylation by 2,2'N, N'-bis(benzyloxycarbonyl)-L-leucinylcarbohydrazide. Inhibition potency varies among proteases tested as reflected by 2-3 orders of magnitude differences in K(i) and K(obs)/I, but all eventually form the same stable covalent intermediate. Reactivation rates are equivalent for all enzymes tested (1 x 10(-)(4) s(-)(1)), indicating hydrolysis of a common carbamyl-enzyme form. NMR spectroscopic studies with cathepsin K and 2,2'-N,N'-bis(benzyloxycarbonyl)-L-leucinylcarbohydrazide provide evidence of inhibitor cleavage to generate a covalent carbamyl-enzyme intermediate rather than a tetrahedral complex. The product Cbz-leu-hydrazide does not appear enzyme-bound after cleavage in the NMR spectra, suggesting that the stable inhibited form of the enzyme is the thioester complex. 1, 5-diacylcarbohydrazides represent a new class of unreactive cysteine protease inhibitors that share a common mechanism of action across members of the papain superfamily. Both S and S' subsite interactions are exploited in achieving high selectivity and potency.


Subject(s)
Cathepsins/antagonists & inhibitors , Hydrazines/pharmacology , Protease Inhibitors/pharmacology , Binding Sites , Cathepsin K , Chromatography, High Pressure Liquid , Enzyme Reactivators , Hydrazines/chemistry , Kinetics , Leucine/analogs & derivatives , Leucine/chemistry , Leucine/pharmacology , Magnetic Resonance Spectroscopy , Mass Spectrometry , Papain/antagonists & inhibitors , Spectrophotometry
5.
Med Res Rev ; 17(1): 17-67, 1997 Jan.
Article in English | MEDLINE | ID: mdl-8979248

ABSTRACT

With the advent of the first generation of both selective and nonselective endothelin antagonists being a relatively recent event, the manifold therapeutic potentials of these compounds are only now being explored clinically. Undoubtedly, numerous clinical utilities for these compounds will soon be realized.


Subject(s)
Endothelins/antagonists & inhibitors , Cardiovascular Diseases/drug therapy , Endothelin Receptor Antagonists , Endothelins/classification , Endothelins/genetics , Endothelins/metabolism , Endothelins/therapeutic use , Humans , Molecular Biology , Receptors, Endothelin/classification , Receptors, Endothelin/genetics , Receptors, Endothelin/metabolism , Signal Transduction , Tissue Distribution
7.
J Med Chem ; 37(19): 3100-7, 1994 Sep 16.
Article in English | MEDLINE | ID: mdl-7932533

ABSTRACT

The rational design and synthesis of a highly potent inhibitor of HIV-1 protease have been accomplished. The inhibitor, SB 206343, is based on a model derived from the structure of the MVT-101/HIV-1 protease complex and contains a 4(5)-acylimidazole ring as an isosteric replacement for the P1'--P2' amide bond. It is a competitive inhibitor with an apparent inhibition constant of 0.6 nM at pH 6.0. The three-dimensional structure of SB 206343 bound in the active site of HIV-1 protease has been determined at 2.3 A resolution by X-ray diffraction techniques and refined to a crystallographic discrepancy factor, R (= sigma parallel Fo magnitude of/Fc parallel/sigma magnitude of), of 0.194. The inhibitor is held in the enzyme by a set of hydrophobic and polar interactions. N-3 of the imidazole ring participates in a novel hydrogen-bonding interaction with the bound water molecule, demonstrating the effectiveness of the imidazole ring as an isosteric replacement for the P1'--P2' amide bond in hydroxyethylene-based HIV-1 protease inhibitors. Also present are hydrogen-bonding interactions between N-1 of the imidazole ring and the carbonyl of Gly-127 as well as between the imidazole acyl carbonyl oxygen and the amide nitrogen of Asp-129, exemplifying the peptidomimetic nature of the 4(5)-acylimidazole isostere. All of these interactions are in qualitative agreement with those predicted by the model.


Subject(s)
Amides/chemical synthesis , Amides/pharmacology , HIV Protease Inhibitors/chemical synthesis , HIV Protease Inhibitors/pharmacology , Imidazoles/chemical synthesis , Imidazoles/pharmacology , Amides/metabolism , Binding Sites , Crystallography, X-Ray , Drug Design , HIV Protease/drug effects , HIV Protease/metabolism , Imidazoles/chemistry , Imidazoles/metabolism , Models, Molecular , Molecular Structure , Reproducibility of Results , Stereoisomerism , Structure-Activity Relationship , Valine/analogs & derivatives , Valine/chemical synthesis , Valine/chemistry , Valine/pharmacology
8.
Methods Enzymol ; 241: 127-56, 1994.
Article in English | MEDLINE | ID: mdl-7854175

ABSTRACT

Despite the current plethora of structural data of HIV-1 protease and the availability of potent inhibitors, whose structures are based in part on the presumed mechanism of action of this enzyme, our actual understanding of its chemical mechanism has been until now based largely on the precedents of the mammalian and fungal aspartic proteases and static three-dimensional data. The available steady state kinetic data of the protease, as reviewed here, constitute a first step in a detailed description of the mechanism of the enzyme to complement the structural data.


Subject(s)
HIV Protease/metabolism , HIV-1/enzymology , Models, Chemical , Amino Acid Sequence , Catalysis , Chromatography, High Pressure Liquid/methods , Chromatography, Ion Exchange/methods , Chromogenic Compounds , Colorimetry/methods , Deuterium/metabolism , Fluorometry/methods , HIV Protease/chemistry , HIV Protease Inhibitors/pharmacology , Hydrogen-Ion Concentration , Hydrolysis , Kinetics , Molecular Sequence Data , Nitrogen Isotopes , Oxygen Isotopes , Peptide Fragments/analysis , Peptides/chemical synthesis , Peptides/metabolism , Radiometry/methods
9.
Biochemistry ; 32(46): 12380-5, 1993 Nov 23.
Article in English | MEDLINE | ID: mdl-8241126

ABSTRACT

We have used 15N kinetic isotope effects of the HIV-1 protease-catalyzed peptidolysis of Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2 to characterize the chemical mechanism of this enzyme. In addition, the multiple isotope effects have been determined by measuring the 15N kinetic isotope effects in both H2O and D2O. The isotope effects, measured on values of V/K, were determined by the incorporation of a radiolabel (tritium and 14C in peptides bearing the heavy and light isotopes, respectively) at a position remote from the isotopically labeled scissile peptide bond, such that the isotope effect was determined by measurement of the change in the 14C/3H ratio in recovered substrates at various fractions of reaction. At pH = 6.0 (37 degrees C), the nitrogen isotope effects were slightly, but significantly, inverse in both solvents: 15(V/K)H2O = 0.995 +/- 0.002, and 15(V/K)D2O = 0.992 +/- 0.003. The observation of an inverse nitrogen kinetic isotope effect implies that bonding to the nitrogen atom is becoming stiffened in a reaction transition state, and since this inverse isotope effect is enhanced in D2O, this isotope effect likely arises from protonation of the proline nitrogen atom.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
HIV Protease/metabolism , HIV-1/enzymology , Amino Acid Sequence , Kinetics , Molecular Sequence Data , Nitrogen Isotopes , Oligopeptides/metabolism , Recombinant Proteins , Structure-Activity Relationship
10.
Biochemistry ; 32(14): 3557-63, 1993 Apr 13.
Article in English | MEDLINE | ID: mdl-8466899

ABSTRACT

HIV-1 protease contains two identical, conformationally mobile loops, known as flaps, which form in part the binding pockets for substrates and inhibitors. We have constructed a site-specific mutant of the protease in which residues Phe-53 and Phe-153 at the end of the flaps have been mutated to Trp residues, in order to incorporate a specific fluorescent probe to monitor conformational changes upon the binding of an inhibitor. The Phe53Trp (F53W) mutant of HIV-1 protease was expressed in Escherichia coli and purified from bacterial lysates. Analysis of the purified mutant protease demonstrated that its kinetic properties were highly similar to those of the wild-type protease. While binding of a potent peptide-analogue inhibitor (Ki = 9 nM) to the wild-type enzyme led to no change in protein fluorescence, a 5-8% increase in fluorescence was observed with the F53W mutant, indicating an enhancement of the Trp fluorescence due to flap movement upon inhibitor binding. Investigation of the kinetics of the F53W protease-inhibitor binding by stopped-flow spectrofluorometry revealed a rapid increase in protein fluorescence upon formation of the enzyme-inhibitor complex. These data were consistent with a one-step mechanistic model of inhibitor binding in which flap movement was concomitant with inhibitor binding, from which respective rate constants of association and dissociation of 2.5 x 10(6) M-1 s-1 and 0.023 s-1 were obtained.


Subject(s)
HIV Protease Inhibitors/metabolism , HIV Protease/chemistry , HIV Protease/metabolism , HIV-1/enzymology , Amino Acid Sequence , Binding Sites , HIV Protease/genetics , Hydrogen-Ion Concentration , Kinetics , Molecular Sequence Data , Molecular Structure , Mutagenesis, Site-Directed , Peptides/metabolism , Phenylalanine/genetics , Protein Conformation , Spectrometry, Fluorescence , Tryptophan/genetics , Tryptophan/metabolism , X-Ray Diffraction
11.
Biochemistry ; 32(3): 937-47, 1993 Jan 26.
Article in English | MEDLINE | ID: mdl-8422397

ABSTRACT

Potential advantages of C2-symmetric inhibitors designed for the symmetric HIV-1 protease include high selectivity, potency, stability, and bioavailability. Pseudo-C2-symmetric monools and C2-symmetric diols, containing central hydroxymethylene and (R,R)-dihydroxyethylene moieties flanked by a variety of hydrophobic P1/P1' side chains, were studied as HIV-1 protease inhibitors. The monools and diols were synthesized in 8-10 steps from D-(+)-arabitol and D-(+)-mannitol, respectively. Monools with ethyl or isobutyl P1/P1' side chains were weak inhibitors of recombinant HIV-1 protease (Ki > 10 microM), while benzyl P1/P1' side chains afforded a moderately potent inhibitor (apparent Ki = 230 nM). Diols were 100-10,000x more potent than analogous monools, and a wider range of P1/P1' side chains led to potent inhibition. Both classes of compounds exhibited lower apparent Ki values under high-salt conditions. Surprisingly, monool and diol HIV-1 protease inhibitors were potent inhibitors of porcine pepsin, a prototypical asymmetric monomeric aspartic protease. These results were evaluated in the context of the pseudosymmetric structure of monomeric aspartic proteases and their evolutionary kinship with the retroviral proteases. The X-ray crystal structure of HIV-1 protease complexed with a symmetric diol was determined at 2.6 A. Contrary to expectations, the diol binds the protease asymmetrically and exhibits 2-fold disorder in the electron density map. Molecular dynamics simulations were conducted beginning with asymmetric and symmetric HIV-1 protease/inhibitor model complexes. A more stable trajectory resulted from the asymmetric complex, in agreement with the observed asymmetric binding mode. A simple four-point model was used to argue more generally that van der Waals and electrostatic force fields can commonly lead to an asymmetric association between symmetric molecules.


Subject(s)
Dipeptides/pharmacology , Glycols/pharmacology , HIV Protease Inhibitors/pharmacology , HIV Protease/drug effects , HIV-1/enzymology , Alcohols/chemistry , Alcohols/metabolism , Dipeptides/chemical synthesis , Dipeptides/chemistry , Dipeptides/metabolism , Glycols/chemical synthesis , Glycols/metabolism , HIV Protease/metabolism , HIV Protease Inhibitors/chemical synthesis , HIV Protease Inhibitors/metabolism , Hydrogen Bonding , Models, Molecular , Pepsin A/antagonists & inhibitors , Protein Conformation , Recombinant Proteins/metabolism , Sensitivity and Specificity , Structure-Activity Relationship
12.
Biochemistry ; 31(47): 11778-84, 1992 Dec 01.
Article in English | MEDLINE | ID: mdl-1445912

ABSTRACT

The rates of desorption of the substrate water from the binary enzyme-H2O and ternary enzyme-H2O-(peptide)substrate complexes for the two hydrolases, porcine pepsin and thermolysin, have been investigated using a novel technique, solvent isotope partitioning. The experimental design of this method was based on the protocol of Rose et al. [Rose, I. A., O'Connell, E. L., Litwin, S., & BarTana, J. (1974) J. Biol. Chem. 249, 5163-5168] wherein the binary enzyme-H2(18)O complex established in the "pulse" solution was diluted into a "chase" solution containing variable concentrations of peptide substrates in a large pool of H2(16)O. The extent of trapping of H2(18)O within the respective E-H2(18)O and E-H2(18)O-(peptide)substrate complexes was determined from mass spectrometric analysis of the hydrolytic products. Our data have shown that the substrate water molecule of pepsin is not exclusively retained in the catalytic cycle and it desorbs from the apo- and substrate-bound complexes at rates that are at least 10 and 4 times faster, respectively, than that of product formation. Similarly, the low trapping of H2(18)O in the carboxylic product of the thermolysin reaction is a consequence of the ready desorption of H2(18)O from the ternary E-H2(18)O-(peptide)substrate complex and the binary E-H2(18)O complex. We attribute these results to the loss of the reactant water molecule due to desolvation of the enzyme's active site upon substrate binding.


Subject(s)
Pepsin A/metabolism , Thermolysin/metabolism , Water/metabolism , Amino Acid Sequence , Animals , Binding Sites , Kinetics , Molecular Sequence Data , Oligopeptides/chemistry , Oligopeptides/metabolism , Oxygen Isotopes , Solvents , Swine
13.
Biochemistry ; 31(39): 9491-501, 1992 Oct 06.
Article in English | MEDLINE | ID: mdl-1390732

ABSTRACT

The free energies of dimer dissociation of the retroviral proteases (PRs) of human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) were determined by measuring the effects of denaturants on the protein fluorescence upon the unfolding of the enzymes. HIV-1 PR was more stable to denaturation by chaotropes and extremes of pH and temperature than SIV PR, indicating that the former enzyme has greater conformational stability. The urea unfolding curves of both proteases were sigmoidal and single phase. The midpoints of the transition curves increased with increasing protein concentrations. These data were best described by and fitted to a two-state model in which folded dimers were in equilibrium with unfolded monomers. This denaturation model conforms to cases in which protein unfolding and dimer dissociation are concomitant processes in which folded monomers do not exist [Bowie, J. U., & Sauer, R. T. (1989) Biochemistry 28, 7140-7143]. Accordingly, the free energies of unfolding reflect the stabilities of the protease dimers, which for HIV-1 PR and SIV PR were, respectively, delta GuH2O = 14 +/- 1 kcal/mol (Ku = 39 pM) and 13 +/- 1 kcal/mol (Ku = 180 pM). The binding of a tight-binding, competitive inhibitor greatly stabilized HIV-1 PR toward urea-induced unfolding (delta GuH2O = 19.3 +/- 0.7 kcal/mol, Ku = 7.0 fM). There were also profound effects caused by adverse pH on the protein conformation for both HIV-1 PR and SIV PR, resulting in unfolding at pH values above and below the respective optimal ranges of 4.0-8.0 and 4.0-7.0


Subject(s)
Aspartic Acid Endopeptidases/chemistry , HIV Protease/chemistry , HIV-1/enzymology , Simian Immunodeficiency Virus/enzymology , Aspartic Acid Endopeptidases/drug effects , Enzyme Stability/drug effects , HIV Protease/drug effects , Hot Temperature , Models, Chemical , Models, Molecular , Protein Conformation/drug effects , Protein Denaturation/drug effects , Protein Structure, Secondary/drug effects , Recombinant Proteins/chemistry , Recombinant Proteins/drug effects , Spectrometry, Fluorescence , Spectrophotometry, Ultraviolet , Thermodynamics , Ultracentrifugation , Urea/pharmacology
14.
Biochemistry ; 31(29): 6646-59, 1992 Jul 28.
Article in English | MEDLINE | ID: mdl-1637805

ABSTRACT

Analogues of peptides ranging in size from three to six amino acids and containing the hydroxyethylene dipeptide isosteres Phe psi Gly, Phe psi Ala, Phe psi NorVal, Phe psi Leu, and Phe psi Phe, where psi denotes replacement of CONH by (S)-CH(OH)CH2, were synthesized and studied as HIV-1 protease inhibitors. Inhibition constants (Ki) with purified HIV-1 protease depend strongly on the isostere in the order Phe psi Gly greater than Phe psi Ala greater than Phe psi NorVal greater than Phe psi Leu greater than Phe psi Phe and decrease with increasing length of the peptide analogue, converging to a value of 0.4 nM. Ki values are progressively less dependent on inhibitor length as the size of the P1' side chain within the isostere increases. The structures of HIV-1 protease complexed with the inhibitors Ala-Ala-X-Val-Val-OMe, where X is Phe psi Gly, Phe psi Ala, Phe psi NorVal, and Phe psi Phe, have been determined by X-ray crystallography (resolution 2.3-3.2 A). The crystals exhibit symmetry consistent with space group P6(1) with strong noncrystallographic 2-fold symmetry, and the inhibitors all exhibit 2-fold disorder. The inhibitors bind in similar conformations, forming conserved hydrogen bonds with the enzyme. The Phe psi Gly inhibitor adopts an altered conformation that places its P3' valine side chain partially in the hydrophobic S1' pocket, thus suggesting an explanation for the greater dependence of the Ki value on inhibitor length in the Phe psi Gly series. From the kinetic and crystallographic data, a minimal inhibitor model for tight-binding inhibition is derived in which the enzyme subsites S2-S2' are optimally occupied. The Ki values for several compounds are compared with their potencies as inhibitors of proteolytic processing in T-cell cultures chronically infected with HIV-1 (MIC values) and as inhibitors of acute infectivity (IC50 values). There is a rank-order correspondence, but a 20-1000-fold difference, between the values of Ki and those of MIC or IC50. IC50 values can approach those of Ki but are highly dependent on the conditions of the acute infectivity assay and are influenced by physiochemical properties of the inhibitors such as solubility.


Subject(s)
Antiviral Agents/chemical synthesis , HIV Protease Inhibitors , HIV-1/physiology , Oligopeptides/chemistry , Oligopeptides/pharmacology , Protease Inhibitors/chemical synthesis , Virus Replication/drug effects , Amino Acid Sequence , Blotting, Western , Cell Line , Ethylenes/chemistry , Ethylenes/pharmacology , HIV Protease/chemistry , HIV Protease/isolation & purification , HIV-1/drug effects , HIV-1/enzymology , Humans , Indicators and Reagents , Kinetics , Models, Molecular , Molecular Sequence Data , Oligopeptides/chemical synthesis , Protein Binding , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Structure-Activity Relationship , Substrate Specificity , T-Lymphocytes , X-Ray Diffraction
15.
Antimicrob Agents Chemother ; 36(5): 982-8, 1992 May.
Article in English | MEDLINE | ID: mdl-1510424

ABSTRACT

Synthetic peptide analog inhibitors of human immunodeficiency virus type 1 (HIV-1) protease were used to study the effects of inhibition of polyprotein processing on the assembly, structure, and infectivity of virions released from a T-cell line chronically infected with HIV-1. Inhibition of proteolytic processing of both Pr55gag and Pr160gag-pol was observed in purified virions from infected T cells after treatment. Protease inhibition was evident by the accumulation of precursors and processing intermediates of Pr55gag and by corresponding decreases in mature protein products. Electron microscopy revealed that the majority of the virion particles released from inhibitor-treated cells after a 24-h treatment had an immature or aberrant capsid morphology. This morphological change correlated with the inhibition of polyprotein processing and a loss of infectivity. The infectivity of virion particles purified from these chronically infected cell cultures was assessed following treatment with the inhibitor for 1 to 3 days. Virions purified from cultures treated with inhibitor for 1 or 2 days demonstrated a 95- to 100-fold reduction in virus titers, and treatment for 3 days resulted in complete loss of detectable infectivity. The fact that virions from treated cultures were unable to establish infection over the 7- to 10-day incubation period in the titration experiments strongly suggests that particles produced by inhibitor-treated cells were unable to reactivate to an infectious form when they were purified away from exogenous protease inhibitor. Thus, a block of HIV-1 protease processing of viral polyproteins by specific inhibitors results in a potent antiviral effect characterized by the production of noninfectious virions with altered protein structures and immature morphologies.


Subject(s)
HIV Protease Inhibitors , HIV-1/drug effects , Virion/drug effects , Blotting, Western , Cells, Cultured , Electrophoresis, Polyacrylamide Gel , HIV-1/pathogenicity , Humans , Microscopy, Electron
16.
J Enzyme Inhib ; 6(1): 65-98, 1992.
Article in English | MEDLINE | ID: mdl-1285304

ABSTRACT

The human immunodeficiency virus (HIV), the etiological agent for the acquired immune deficiency syndrome (AIDS), is a retrovirus which makes use of a virally-encoded aspartic protease to perform specific proteolytic processing of two of its gene products in order to form active enzymes and structural proteins within the mature virion. Accordingly, specific, exogenous inhibition of the HIV-1 protease is thought to be a viable approach for the development of novel therapeutics for the treatment of AIDS. Indeed, this hypothesis has been validated in virally-infected cell culture with synthetic inhibitors of HIV-1 protease. This chapter reviews the current status of the development of inhibitors of this enzyme.


Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Antiviral Agents/pharmacology , HIV Protease Inhibitors/pharmacology , HIV Protease/metabolism , HIV-1/enzymology , Amino Acid Sequence , Antiviral Agents/therapeutic use , HIV Protease Inhibitors/therapeutic use , HIV-1/drug effects , HIV-1/growth & development , Molecular Conformation , Molecular Sequence Data , Substrate Specificity , Virus Replication
17.
Biochemistry ; 30(34): 8424-34, 1991 Aug 27.
Article in English | MEDLINE | ID: mdl-1883829

ABSTRACT

Simian immunodeficiency virus protease (SIV-PR) was produced in Escherichia coli with a recombinant expression system in which the mature enzyme autoprocessed from a precursor form. Recombinant SIV and HIV-1 (human immunodeficiency virus, type 1) proteases were purified from bacterial cell lysates by use of sequential steps of ammonium sulfate precipitation and size-exclusion and ion-exchange chromatography. The amino acid composition, amino-terminal sequence, and molecular weight (monomer) of the recombinant SIV-PR were in accord with that of the 99 amino acid polypeptide predicted from the SIVMac-PR nucleotide sequence. The active form of SIV-PR was shown to be dimeric by gel filtration chromatography. Inhibition by pepstatin A, time-dependent inactivation by 1,2-epoxy-3-(4-nitrophenoxy)propane, and pH rate profiles using oligopeptide substrates demonstrated that SIV-PR behaves as an aspartic protease. Recombinant HIV-1 Pr55gag precursor was processed in vitro by SIV-PR and HIV-1 PR with indistinguishable proteolytic patterns upon NaDodSO4-polyacrylamide gel electrophoresis. Oligopeptide substrates for HIV-1 PR were found to be suitable substrates for recombinant SIV-PR with the exception of a peptide containing the site identified for p66/p51 cleavage (Phe*Tyr) within HIV-1 reverse transcriptase (RT). Several synthetic peptide analogue inhibitors of HIV-1 PR were also potent inhibitors of SIV-PR, indicating that SIV infection in macaques and rhesus monkeys should be useful models for the preclinical evaluation of acquired immunodeficiency syndrome (AIDS) therapeutics targeted towards the virally encoded HIV-1 protease.


Subject(s)
Endopeptidases/isolation & purification , HIV Protease/isolation & purification , HIV-1/enzymology , Retroviridae Proteins/isolation & purification , Simian Immunodeficiency Virus/enzymology , Amino Acid Sequence , Animals , Endopeptidases/chemistry , Endopeptidases/classification , HIV Protease/classification , HIV Protease/genetics , HIV Protease Inhibitors , HIV-1/growth & development , Hydrogen-Ion Concentration , Isoelectric Focusing , Molecular Sequence Data , Peptides/chemical synthesis , Peptides/pharmacology , Protein Conformation , Protein Synthesis Inhibitors/pharmacology , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/biosynthesis , Recombinant Proteins/classification , Recombinant Proteins/isolation & purification , Retroviridae Proteins/antagonists & inhibitors , Retroviridae Proteins/classification , Retroviridae Proteins/genetics , Simian Immunodeficiency Virus/physiology , Substrate Specificity
18.
Biochemistry ; 30(34): 8454-63, 1991 Aug 27.
Article in English | MEDLINE | ID: mdl-1883831

ABSTRACT

The pH dependence of the peptidolytic reaction of recombinant human immunodeficiency virus type 1 protease has been examined over a pH range of 3-7 for four oligopeptide substrates and two competitive inhibitors. The pK values obtained from the pKis vs pH profiles for the unprotonated and protonated active-site aspartyl groups, Asp-25 and Asp-25', in the monoprotonated enzyme form were 3.1 and 5.2, respectively. Profiles of log V/K vs pH for all four substrates were "bell-shaped" in which the pK values for the unprotonated and protonated aspartyl residues were 3.4-3.7 and 5.5-6.5, respectively. Profiles of log V vs pH for these substrates were "wave-shaped" in which V was shifted to a constant lower value upon protonation of a residue of pK = 4.2-5.2. These results indicate that substrates bind only to a form of HIV-1 protease in which one of the two catalytic aspartyl residues is protonated. Solvent kinetic isotope effects were measured over a pH (D) range of 3-7 for two oligopeptide substrates, Ac-Arg-Ala-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2 and Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2. The pH-independent value for DV/K was 1.0 for both substrates, and DV = 1.5-1.7 and 2.2-3.2 at low and high pH (D), respectively. The attentuation of both V and DV at low pH (D) is consistent with a change in rate-limiting step from a chemical one at high pH (D) to one in which a product release step or an enzyme isomerization step becomes partly rate-limiting at low pH (D). Proton inventory data is in accord with the concerted transfer of two protons in the transition state of a rate-limiting chemical step in which the enzyme-bound amide hydrate adduct collapses to form the carboxylic acid and amine products.


Subject(s)
HIV Protease/chemistry , Amino Acid Sequence , Binding Sites , Binding, Competitive , Catalysis , Hydrogen-Ion Concentration , Kinetics , Molecular Sequence Data , Oligopeptides/chemistry , Oxygen Isotopes , Solvents , Substrate Specificity
19.
Anal Biochem ; 197(1): 225-30, 1991 Aug 15.
Article in English | MEDLINE | ID: mdl-1952069

ABSTRACT

We have demonstrated the use of a radioimmunoassay to quantitate the peptidolytic activity of human immunodeficiency virus, type 1 (HIV-1) protease using a tetradecapeptide substrate of porcine renin, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser. HIV-1 protease catalyzes cleavage of this substrate at the same Leu-Leu bond as does porcine renin, resulting in the formation of authentic angiotensin-I. The angiotensin-I product is then detected by use of a commercially available renin plasma assay kit, which constitutes the basis of the RIA. The radioimmunoassay provides detection of the protease-catalyzed formation of angiotensin-I at picomolar concentrations in vitro. We demonstrate the use of this assay in determining IC50 values for two HIV-1 protease inhibitors present in cell culture media and in standard assay buffer. An example of the potential development of this assay for the quantitation of these inhibitors present in ex vivo plasma samples is also presented.


Subject(s)
HIV Protease/blood , Radioimmunoassay/methods , Renin/blood , Amino Acid Sequence , Animals , HIV Protease Inhibitors , Humans , In Vitro Techniques , Molecular Sequence Data , Peptides/chemistry , Peptides/pharmacology , Protease Inhibitors/chemistry , Protease Inhibitors/pharmacology , Substrate Specificity , Swine
20.
Anal Biochem ; 188(2): 408-15, 1990 Aug 01.
Article in English | MEDLINE | ID: mdl-2221392

ABSTRACT

A rapid, high-throughput radiometric assay for HIV-1 protease has been developed using ion-exchange chromatography performed in 96-well filtration plates. The assay monitors the activity of the HIV-1 protease on the radiolabeled form of a heptapeptide substrate, [tyrosyl-3,5-3H]Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2, which is based on the p17-p24 cleavage site found in the viral polyprotein substrate Pr55gag. Specific cleavage of this uncharged heptapeptide substrate by HIV-1 protease releases the anionic product [tyrosyl-3,5-3H]Ac-Ser-Gln-Asn-Tyr, which is retained upon minicolumns of the anion-exchange resin AG1-X8. Protease activity is determined from the recovery of this radiolabeled product following elution with formic acid. This facile and highly sensitive assay may be utilized for steady-state kinetic analysis of the protease, for measurements of enzyme activity during its purification, and as a routine assay for the evaluation of protease inhibitors from natural product or synthetic sources.


Subject(s)
Chromatography, Ion Exchange , HIV Protease/metabolism , Amino Acid Sequence , Hydrogen-Ion Concentration , Kinetics , Molecular Sequence Data , Reproducibility of Results , Substrate Specificity , Tritium
SELECTION OF CITATIONS
SEARCH DETAIL
...